Some antihyperglycemic agents used to treat T2D, such as insulin, sulfonylureas and thiazolidinediones, can lead to weight gain and frequent episodes of hypoglycemia, which are associated with reduced quality of life and increased cardiovascular events. Here, INS is linked to Hypoglycemia.